 Travere Therapeutics Inc NASDAQ: TVTX shares are trading higher by 7.66 at 23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy. Travere Therapeutics says the FDA has indicated that it is not currently planning to hold an advisory committee. 